September 21, 2018 09:50 AM EDTUpdated May 26, 08:50 PM

Novartis drums up EU launch plans as CHMP gives thumbs up to Spark's gene therapy Luxturna

Amber Tong

Nine months after the FDA gave its landmark OK for Spark Therapeutics’ trailblazing gene therapy Luxturna, European regulators have signaled that they are ready to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis drums up EU launch plans as CHMP gives thumbs up to Spark's gene therapy Luxturna

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

No­var­tis drums up EU launch plans as CHMP gives thumbs up to Spark's gene ther­a­py Lux­tur­na

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Novartis drums up EU launch plans as CHMP gives thumbs up to Spark's gene therapy Luxturna

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Food allergy biotech Alladapt closes after Phase 3 talks with FDA